Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2016-0021
Abstract: AIM To explore whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those investments rather than levels of burden of illness (BI). METHODS Associate the number of translational clinical trials in… read more here.
Keywords: research; translational sciences; metastatic cancers; investments translational ... See more keywords